

Edgar Filing: BIOENVISION INC - Form 8-K

BIOENVISION INC  
Form 8-K  
March 25, 2004

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 8-K

Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 22, 2004  
-----

BIOENVISION, INC.  
-----

(Exact Name of Registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of incorporation)	000-24875 ----- (Commission File Number)	13-4025857 ----- (IRS Employer Identification No.)
--	---	---

509 Madison Avenue, Suite 404, New York, New York 10022  
-----

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:  
(212) 750-6700  
-----

Not Applicable  
-----

(Former name or former address, if changed since last report)

Item 9. Regulation FD Disclosure.

On March 22, 2004, Bioenvision, Inc., a Delaware corporation (the "Company"), entered into a Common Stock and Warrant Purchase Agreement (the "Purchase Agreement") with certain existing and new institutional investors (the "Investors"), pursuant to which the Company issued and sold 2,044,514 shares of the Company's common stock, par value \$0.001 per share, at a per share purchase price of \$6.25, together with warrants to purchase 408,903 shares of common stock, at an exercise price of \$7.50 per share. Further, the Company issued warrants to purchase 204,452 shares of common stock, at an exercise price of \$6.25 per share, to SCO Securities LLC, its exclusive financial advisor in connection with this financing. The Purchase Agreement is attached hereto as

Edgar Filing: BIOENVISION INC - Form 8-K

Exhibit 4.1.

On March 22, 2004, the Company entered into a Registration Rights Agreement with the Investors and SCO Securities LLC, a Delaware limited liability company, as placement agent (the "Registration Rights Agreement"), pursuant to which the Company shall prepare and file with the Securities and Exchange Commission one registration statement covering the resale of the securities issued and sold in the Purchase Agreement as well as such indeterminate number of additional shares of the Company's common stock resulting from stock splits, stock dividends or similar transactions with respect to such securities. The Registration Rights Agreement is attached hereto as Exhibit 4.2.

On March 22, 2004, the Company issued to the Investors warrants to purchase one-fifth of a share of common stock at an exercise price of \$7.50 per share. The form of warrant is attached hereto as Exhibit 4.3.

On March 23, 2004, the Company issued a press release announcing that it had raised \$12.8 million through the sale to Investors of approximately 2 million shares of common stock as well as warrants to purchase approximately 400,000 shares of additional common stock, excluding warrants to SCO Securities LLC for acting in its capacity as exclusive financial advisor to the Company. A copy of the press release is attached hereto as Exhibit 99.1.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOENVISION, INC.

March 24, 2004

By: /s/ David P. Luci

-----  
David P. Luci  
Director of Finance, General Counsel  
and Corporate Secretary

Exhibit Index

-----

Exhibit No. -----	Exhibit -----
4.1	Common Stock and Warrant Purchase Agreement, dated as of March 22, 2004, by and among Bioenvision, Inc. (the "Company") and the Investors set forth on Schedule I thereto (the "Investors").
4.2	Registration Rights Agreement, dated as of March 22, 2004, by and among the Company, the Investors and SCO Securities LLC.

Edgar Filing: BIOENVISION INC - Form 8-K

- 4.3 Form of Warrant
- 99.1 Press Release, dated March 23, 2004, announcing the issuance and sale of common stock and warrants to the Investors.